SomnoMed launches new product to treat sleep bruxism

SomnoMed has launched the new SomnoMed Brux (SomBrux) range, an innovative new set of products for treating sleep bruxism. Sleep Bruxism is a common sleep-related movement disorder that is characterised by clenching or grinding of the jaws or teeth.

Medical studies indicate a prevalence of approximately 8% in the adult population of western societies and an equal occurrence in men and women. The condition is currently treated with a wide range of products, mostly individually made by dental technicians.

The new SomnoMed Brux product line is initially being introduced in Australia and will be followed throughout the year by launches in all major global markets where SomnoMed is represented. SomBrux, like the leading SomnoDent device treating sleep apnea, is custom made and offered in various designs. It is expected that one of its unique selling points is the use of SomnoMed's SMH BFlex material, which offers unrivalled patient comfort and durability.

SomnoMed's CEO Mr Ralf Barschow commented, "SomnoMed's mission is to treat sleep related disorders, such as snoring, sleep apnea and bruxism. Teeth clinching or grinding is one of the most frequent medical conditions occurring during sleep. Our knowledge of the impact of bruxism on teeth and jaws, breathing, neck and back conditions, even general health is evolving but generally considered by practitioners as significant. SomBrux is our treatment answer for this condition and satisfies a potential demand from a significant number of patients around the world. It is a logical next step in our dental sleep appliance product range, offering a combination of highest quality and excellent craftsmanship, synonymous with all our SomnoMed products.

"SomnoMed is now ideally positioned for the introduction of an additional product line with the worldwide dedicated distribution network of more than 2,000 SomnoMed dental network practices, which the company has built over the last three years. Our existing production facilities are scalable and will be able to cater for the expected demand for this innovative product line, which is recognized and reimbursed by most health insurances worldwide."